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of health interventions for drug and
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Abstract
Background: The overarching goal of health policies is to maximize health and societal benefits. Economic
evaluations can play a vital role in assessing whether or not such benefits occur. This paper reviews the application
of modelling techniques in economic evaluations of drug and alcohol interventions with regard to (i) modelling
paradigms themselves; (ii) perspectives of costs and benefits and (iii) time frame.
Methods: Papers that use modelling approaches for economic evaluations of drug and alcohol interventions were
identified by carrying out searches of major databases.
Results: Thirty eight papers met the inclusion criteria. Overall, the cohort Markov models remain the most popular
approach, followed by decision trees, Individual based model and System dynamics model (SD). Most of the papers
adopted a long term time frame to reflect the long term costs and benefits of health interventions. However, it was
fairly common among the reviewed papers to adopt a narrow perspective that only takes into account costs and
benefits borne by the health care sector.
Conclusions: This review paper informs policy makers about the availability of modelling techniques that can be used
to enhance the quality of economic evaluations for drug and alcohol treatment interventions.
Keywords: Substance abuse, Drug dependence, Alcohol dependence, Economic evaluation, Modelling
Background
Economic evaluations and the role of modelling
The economic, social and health consequences related to
the consumption of drug and alcohol are a global con-
cern with 0.8 % of the global all-cause disability adjusted
life years (DALYs) attributable to illicit drugs and alcohol
[1]. Governments are faced with difficult decisions of
how to best to allocate the limited available resources in
order to maximise the value of spending (e.g. to achieve
the highest net/social benefit). Modelling is frequently
being applied as a method of depicting the complexity of
decision making with respect to interventions and to
more accurately capture associated costs and benefits in
economic evaluations.
Modelling can be broadly defined as the reproduction
of events and possible consequences due to alternative
policy options at the cohort or individual levels using
mathematical and statistical framework. In the drug and
alcohol area, models have been developed, for example,
to mimic the heroin use and treatment profile of individ-
uals over their life time, from which realistic outcomes
can be calculated [2, 3]. Despite modelling being widely
applied for analysis of treatment for alcohol and drug
problems, comprehension about which models are suit-
able to use for which research questions and how to in-
terpret the results and caveats of the models remains
limited. The primary aim of this paper, therefore, is to
review the use of economic modelling in the evaluation
of drug and alcohol treatment. Three modelling aspects
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are the focus of this review: (i) modelling approaches,
(ii) perspectives of costs and benefits, and (iii) time
frame (e.g. short or long-term time frame). Additionally,
the concerns and relevance of each type of model will be
discussed.
Decisions about the perspective of costs and benefits
may have substantial impacts on the modelled outcomes
due to the multiplicity of effects of interventions such as
crime, transmission of infectious diseases, and other
long-term consequences of drug and alcohol depend-
ence. We adopt four distinct perspectives of costs and
benefits according to common definitions in health eco-
nomics as follows: “(i) individual patient — all conse-
quences that accrue to the patient and all costs that are
borne by the patient; (ii) health funder — for example,
the costs that fall on a State health authority; (iii) health
care sector — all costs that fall to the health sector, in-
cluding, but not limited to, hospitals, specialists, general
practitioners, ancillary services and community services
(includes all health improvements or health-related
quality-of-life improvements but does not include such
things as informal carer costs, patient transport costs or
time off work); and (iv) society — all costs and conse-
quences that arise from the options no matter who pays
or who receives benefits from them” [4]. In addition, dif-
ferent types of interventions may generate immediate or
long-term effects. Therefore, for an economic evaluation
to provide relevant policy advice, it should carefully ac-
count for the major costs and benefits and relevant
time-frame associated with each intervention.
Modelling classifications
Economic evaluation is defined as a tool to compare the
costs and benefits of alternative interventions, treat-
ments or policy options. There is a suite of evaluation
methods in health care research that may be used for
different purposes. The search for information on effi-
ciency often leads to an economic evaluation being con-
ducted. Typically these have been cost-effectiveness
(CEA) studies [5–7] or cost-utility (CUA) studies [8, 9].
While CEA and CUA studies can provide evidence to
make the case for the investment in one treatment over
another, the typically short-term time frame of the stud-
ies in the drug and alcohol field (e.g. 3 to 12 months)
[10, 11] and the necessity to choose a single outcome
means that they can fail to capture the full spectrum of
costs and benefits. The single outcome, the narrow per-
spective taken by many studies and the exclusion of exter-
nalities such as costs of crime has led some to call for a
greater focus on cost benefit analyses (CBA) when asses-
sing interventions in the drug and alcohol field [12].
Cost-benefit analysis (CBA), with their outcomes
valued in monetary terms, allows for the inclusion of a
broader range of outcomes and externalities. It is,
however, this inclusion in the CBA of a range of out-
comes, and the necessity to value them in monetary
terms that provides a number of challenges when con-
ducting a CBA [13].
For those who are dependent on drug and alcohol
there maybe movement in and out of treatment and
prison, and the presence of co-morbid medical condi-
tions such as anxiety disorders, depression, HIV/AIDs,
Hepatitis C, and overdose [14–16]. Short-term economic
evaluations conducted alongside RCTs are not usually
sufficient to capture this multiplicity of outcomes. This
problem has been long recognised when conducting
economic evaluations of interventions for chronic ill-
nesses. For example, in areas such as diabetes and heart
disease there has been a shift to the use of economic
modelling which can account for a multiplicity of out-
comes and the long term and complex nature of the
disease [17, 18].
The improvements in computer technology and devel-
opment of new methods have made modelling a power-
ful tool to inform health policies. Through the synthesis
of evidence from multiple datasets on the impact of
interventions, behaviour changes of the individual and
externalities, models can be constructed to compare the
alternative interventions over a long timeframe. In gen-
eral, modelling offers several advantages including: (i)
extrapolating beyond the data observed in a trial; (ii)
linking intermediate clinical endpoints to final outcomes;
(iii) generalizing to other settings; (iv) synthesizing head-
to-head comparisons where relevant; and (v) informing
decisions in the absence of hard data [19]. Broadly, a
model includes four components: (i) the individuals/co-
hort under study; (ii) the states; (iii) the rules of transi-
tion between states over time; and (iii) the associated
costs and benefits attached in each state. The complexity
of a model depends on how the model components are
defined. There exist several classification systems for
health economic models. For example, Brennan et al.
[20] proposes a classification based on whether a model
is cohort or individual-based, discrete or continuous
time-dependent and whether or not it allows for interac-
tions between individuals. As with many classification
systems, simplifications are often necessary to nudge the
models into fixed categories, and many models may ac-
tually cross boundaries. Table 1 provides examples of
common modelling paradigms classified according to
two criteria proposed by Brennan et al. [20].
Decision tree models are the simplest and historically
the most widely used form of models in health econom-
ics: all patient pathways are clearly laid out with their as-
sociated probabilities and outcomes (i.e. costs related to
events, mortality rate, and the probability of committing
crime) which are entered at the terminal node. The
mean value of each decision in the tree is calculated by
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summing probabilities associated with each outcome.
These models are usually used when the time frame is
short, the process is not complicated, reoccurring events
are not important, there is little heterogeneity between
individuals in terms of outcomes and there is no inter-
action between individuals [20–22].
Cohort Markov models are suited to circumstances
where the order of events is important, events may repeat,
and the events may occur over a longer period of time.
However, in addition to not allowing interaction between
individuals in the model, cohort Markov models do not
allow the probability of transitioning to another state in
the model to depend upon the time spent in that state or
previous history [20]. System dynamic models are also
cohort-based models but allow interaction among entities
by modelling the rate of change of the system to be
dependent on the system itself (i.e. feedback loops).
Individual-based models can simulate a richer hetero-
geneity of individual trajectories, allowing for more real-
istic and complex patterns of disease evolution to
emerge. For example, Individual-based microsimulation/
Markov microsimulation can simulate the life-time tra-
jectories of participants and record participants’ history.
The transitions across different states may be condi-
tional on previous events/history that participants have
gone through. Agent-based models (ABM) include au-
tonomous agents whose behaviour depends upon their
past and current internal states, as well as states from
other agents and their environment. Discrete event simu-
lations (DES) allow for both modelling individual trajec-
tories and interaction between entities in the system [20].
It is apparent, even from these brief descriptions, that
different models are appropriate for different purposes. For
example, models which are being used to generate evidence
surrounding communicable disease will need to account
for interaction between agents (i.e. ABM, DES) whereas a
brief intervention for low risk alcohol consumption may
only require a decision tree model. In order for the results
to be meaningful, the choice of a modelling paradigm needs
to reflect the problem being addressed and its context.
Methods
Papers that use modelling approaches for economic
evaluations of drug and alcohol health interventions
were identified by carrying out searches on major data-
bases including: SCOPUS, Medline, CINAHL, PyscInfo,
EconLit and ISI Web of Sciences. The search terms
were: (drug dependence treatment OR substance abuse
OR heroin OR methadone OR buprenorphine OR cocaine
OR Methamphetamine OR Cannabis OR opioid de-
pendence OR alcohol OR dependence) AND (economic
evaluation OR cost-effectiveness OR cost-utility OR cost-
benefit) AND (model* OR simulation). The inclusion
criteria were: (i) economic evaluation studies of drug and
alcohol health interventions; (ii) incorporating a modelling
approach; (iii) peer-reviewed articles in academic journals
published in the period from database inception to
September 2015 in the English language. The exclusion
criteria, therefore, were papers that were not economic
evaluation, did not use modelling or were not about drug
and alcohol health interventions. Accordingly, there were
drug and alcohol modelling studies that were not met in-
clusion criteria such as: the simulation of the life course of
cannabis use [23]; the simulation of Australian drug
markets [24]; the examination of the impact of ecstasy
pill-testing on the prevalence of harms [25] and exploring
policy options and risks for alcohol consumption [26, 27].
Ethics for this study was not required because this
study involved the analysis of published literature.
The initial search of databases yielded 1405 papers; 751
duplicate and unrelated papers were eliminated by check-
ing titles, resulting in 654 papers. Next, each abstract was
reviewed during which 81 papers were selected. The final
step was to conduct in-depth content review of the
selected papers with respect to modelling approach and
economic evaluation framework. Those papers that were
not a cost-benefit, a cost-effectiveness, or a cost-utility
analysis of a health intervention for drug or alcohol prob-
lems, and did not use modelling methods were excluded
(n = 43 exclusions). Finally, 38 papers were included in the
review (see Fig. 1 and Additional file 1). During all screen-
ing steps, a set of papers was allocated to two authors so
that each paper was screened independently twice. Any
discrepancy in the selection of papers was discussed
between the authors to reach a mutual agreement.
Results
Tables 2 and 3 present a summary of classifications of
reviewed papers in regarding to: modelling approaches,
perspectives on costs and benefits and time frame.
Modelling approaches
In terms of types of model, decision trees were used in
11 papers (29 %), cohort-based Markov modelling in 20
papers (52 %), system dynamics in 3 papers (8 %), indi-
vidual based model in 2 papers (5 %) and another model
Table 1 Classification of modelling paradigms
Cohort-based Individual-based
No interaction allowed Decision treeCohort Markov model Individual-based microsimulation/Markov microsimulation
Interaction allowed System dynamics model Agent based modelDiscrete event simulation
Adapted from Brennan et al. [21]
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Table 2 Classifications of reviewed papers
Models used Decision Tree
(n = 11)
Cohort Markov
(n = 20)
Individual-based
microsimulation
Models (n = 2)
System Dynamics
Model (n = 3)
Other Models
(n = 2)
Total
(n = 38)
Design - Aggregate - Aggregate - Individual - Aggregate - Aggregate
- No accounting for
heterogeneity
- Limited
heterogeneity
by using states
- Flexibility to include
heterogeneity by
using transition
probability function
- Limited
heterogeneity by
using states
- No
heterogeneity
- Untimed - Timed - Timed - Timed - Untimed: only
before and after
intervention
- No history - No history - History - No history
- Allow interactions
- No history
Perspective of
Costs and Benefits
Health care
sector
6 17 0 3 0 26
Societal 5 3 2 0 2 12
Timeframe 0-1 year 5 1 0 0 0 6
1-10 years 3 5 0 1 0 9
10 years to
life time
3 14 2 2 2 23
Fig. 1 Flow chart of literature search
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Table 3 Summary of papers and classification of modelling approaches, timeframe and perspectives in costs and benefits
Authors/year of study and summary Country Year of
study
Analytic
method
Study participants Modelling
approach
Time
frame
Perspective on
costs and benefits
Barbosa et al. (2010) [41] have used a cohort based
probabilistic lifetime Markov model where alcohol
consumption and drinking history are used for classifying
patients into 4 Markov states. One year cycle length
was used for the model. The main outcomes were QALYs
and lifetime costs.
The U.K 2010 CEA Males who are seeking alcohol
treatment
Markov Life time Health care sector
Barnett et al. (2001) [8] have developed a dynamic
compartmental model to estimate the effect of adding
buprenorphine maintenance therapy to the US healthcare
system. The model divides population into mutually
exclusive groups (“compartments”) based on HIV status
and drug use status. Transitions between these
compartments were modelled as a system of non-linear
differential equations. Current healthcare costs and
outcomes with the adoption of buprenorphine under
different scenarios were compared.
The U.S 2001 CEA Current population of methadone
treatment participants in the U.S
health care system
Markov 10 years Health care sector
Coffin and Sullivan (2013) [42] employs integrated cohort
based Markov and decision analytic model to assess
cost-effectiveness of distributing naloxone to heroin users
in the U.S over lifetime. In the model, heroin users enter the
model in ‘Heroin use’ state and can make transitions to
‘discontinue and relapse’, ‘overdose’, or ‘death by other
reasons’ state. The ‘overdose’ state triggers a decision tree
based model based on naloxone distribution to assess
whether an individual will survive or die after overdose.
The U.S 2013 CEA Hypothetical 21-year-old novice U.S.
heroin user
Markov Life time Societal
Downs and Klein (1995) [28] developed cost-effectiveness
model based on decision trees for adolescent population
(15-19 years). The intervention is screening visits for alcohol
abuse and unsafe sexual activity.
The U.S 1995 CEA Adolescents aged 15 to 19 years Decision trees 5 years Societal
Magnus et al. (2012) [39] modelled economic and health
gains on the basis of an absolute change in alcohol
consumption. They modelled population simulation model
to determine lifetime benefits of a reduction in per capita
alcohol consumption from 2008 Australian adult cohort
(aged≥ 15 years). It considers workforce production gains
model, household production and leisure time model, and
health sector cost estimates for economic benefit evaluation.
This study aims to evaluate the benefits of reduction of
alcohol use thanks to a hypothetical intervention.
Australia 2012 N/A The 2008 Australian population Aggregate model Lifetime Societal
Navarro et al. (2011) [29] developed a decision tree based
model to assess outcomes and costs of GP-delivered
intervention for alcohol misuse. Nine difference scenarios
with incremental increase in screening, brief intervention, or
in the combination of screening and brief intervention were
compared to current practice.
Australia 2011 CEA Risky drinkers in 10 rural communities
in New South Wales, Australia
Decision trees 1 year Health care sector
H
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Table 3 Summary of papers and classification of modelling approaches, timeframe and perspectives in costs and benefits (Continued)
Purshouse et al. (2013) [30] developed a health economic
model combining the healthcare resource requirements for
alcohol screening and brief intervention with an
epidemiological model of relationships between alcohol
consumption and health harms.
England 2013 CEA Risky drinkers who are screened
through GP’s visits
Decision trees 30 years Health care sector
Sheerin et al. (2004) [40] used Markov model to model
cohorts of injecting drug users, changes in their health
states and effects of methadone maintenance therapy and
anti-viral therapy on morbidity and mortality.
New Zealand 2004 CEA Injecting drug users (IDUs) Markov Lifetime Health care sector
Wammes et al. (2012) [59] used Asian epidemic model and
resource needs model to evaluate the long term preventive
impact of expanding methadone maintenance therapy in
West Java. In this model, population is divided into 8
compartments and individuals move from one compartment
to another based on a transition probabilities.
Indonesia 2012 CEA Injecting drug users (IDUs) Markov 20 years Societal
Tran et al. (2012) [32] developed a simulated decision tree
based model to represent HIV-positive drug user’s transition
to 4 health state within one year horizon. Each of the states
had services cost and health outcomes which were used for
cost and benefit assessments.
Vietnam 2012 CEA HIV-positive drug users Decision trees 1 year Health care sector
Zaric et al. (2000) [43] developed a dynamic compartmental
model to assess the effects of increased methadone
maintenance capacity on healthcare costs and survival
(QALYs) for HIV epidemic in a population aged 18-44years.
Population is divided into 9 subgroups based on risk group
and HIV infection status. Size of each compartment over time
is modelled with the help of set of non-linear differential
equations.
The U.S 2000 CEA The population of adults, aged 18 to
44
Markov 10 years Health care sector
Tariq et al. (2009) [44] used a RIVM model to conduct a CEA
of screening and brief intervention for alcohol in primary
care targeting at reisk drinkers; outcomes were ICER, costs
and QALY.
The
Netherlands
2009 CEA Risky drinkers aged between 20 and
65 who visit the GP yearly (50 %)
Markov 80 years Health care sector
van den Berg et al. (2008) [45] used chronic disease model
(CDM) to estimate the cost effectiveness of an alcohol tax
increase from a health care perspective in the Netherlands;
the outcomes were QALYs and LYS and health care costs
The
Netherlands
2008 CEA Current Dutch population Markov 100 years Health care sector
Vickerman et al. (2012) [36] used a system of differential
equations to examine the impact on Hepatitis C of scaling
up OST and needle syringe programs;
The U.K 2012 CEA Injecting Drug Users (IDUs) System dynamics 20 years Health care sector
Nosyk et al. (2012) [46] used a semi Markov cohort model to
assess the increemental cost effectiveness of methadone
versus diacetylmorphine in a cohort who had multiple
failures of OST ; used data from the North American Opiate
Medication Initiative trial; Outcomes used were QALYs and
social costs (treatment, HIV, crime, calculated an ICER)
Canada 2012 CEA Injective drug users (IDUs) Markov Life time Societal
Zaric and Brandeau (2001) [37] used an epidemic model to
determine optimal allocation of HIV prevention funds. Three
The U.S 2001 a population of injection drug users
(IDUs) and non-IDUs
System dynamics 3 years Health care sector
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Table 3 Summary of papers and classification of modelling approaches, timeframe and perspectives in costs and benefits (Continued)
types of programs NSP (1), methadone (2), and condoms (3).
Outcomes were QALYs gained; and the investment portfolio
that maximises the number of HIV cases averted
Resource
allocation
framework
Mortimer and Segal (2005) [47] used a time dependent
state-transition model to compare complementary and
competing interventions for prevention or treatment of
alcohol misuse and dependence; compares usual care with
interventions. Assesses proportions of patients drinking
beyond specified threshold, at 6,12 months follow-up; costs;
cost utility; used QALY league tables
Australia 2005 CEA Problem alcohol drinkers Markov Life time Health care sector
Palmer et al. (2000) [48] uses a Markov model to explore the
long term clinical and economic outcomes of alcohol
maintenance with counselling or counselling plus
accamprosate. Discounted and non-discounted LE and life
time costs, incremental cost effectiveness; uses abstinence.
Germany 2000 CEA Problem alcohol drinkers Markov Life time Health care sector
Zaric et al. (2000) [49] uses a dynamic compartmental model
of HIV to assess the cost effectiveness of MMT as a method
of preventing HIV infection; the outcomes of the model are
discounted LYS and QALYs and discounted health care and
treatment costs
The U.S 2000 CEA Injective drug users (IDUs) Markov 10 years Health care sector
Adi et al. (2007) [31] investigates the clinical effectiveness
and cost effectiveness of naltrexone for relapse prevention
in detoxified opioid dependent persons compared to
psychosocial support.
The U.K 2007 CEA Injective drug users (IDUs) Decision trees 1 year Societal
Barnett (1999) [50] examined cost effectiveness of methadone
compared to standard care among cohort of 25 years old
heroin users in the U.S.
The U.S 1999 CEA Injective drug users (IDUs) Markov Life time Health care sector
Bayoumi (2008) [51] examined cost effectiveness of medically
supervised injecting centre; compared situation with
supervised injecting centre to no injecting centre but with
needle syringe programs.
Canada 2008 CEA Injection drug users and persons
infected with HIV and hepatitis C
virus
Markov 10 years Health care sector
Alistar et al. (2011) [60] have developed a dynamic compartment
model of a population of IDUs on methadone substitution
therapy, IDUs injecting opiates and non-IDUs in order to
evaluate the effectiveness and cost effectiveness of
expanding methadone substitution therapy to IDUs,
increasing access to ART, or both. The outcome measures are
the cost-effectiveness and QALYs.
Ukraine 2011 CEA A population of non-IDUs, IDUs who
inject opiates, and IDUs in MMT,
adding an oral PrEP program
(tenofovir/emtricitabine, 49 %
susceptibility reduction) for
uninfected IDUs
Markov 20 years Health care sector
Kapoor et al. (2009) [52] examine cost-effectiveness of various
screening strategies for unhealthy alcohol use with %
Carbohydrate Deficient Transferrin using a Markov model.
The U.S 2009 CEA Adult men and women (ages 18 to
100 years) in primary care
Markov Life time Health care sector
Schackman et al. (2015) [62] evaluate the cost-effectiveness
of long-term office-based buprenorphine/naloxone treatment
for clinically stable opioid-dependent patients compared to
no treatment.
The U.S 2012 CEA Cohort of clinically stable opioid-
dependent individuals who have
already completed 6 months of
office-based buprenorphine/naloxone
treatment
Markov 2 year Health care sector
H
oang
et
al.BM
C
H
ealth
Services
Research
 (2016) 16:127 
Page
7
of
14
Table 3 Summary of papers and classification of modelling approaches, timeframe and perspectives in costs and benefits (Continued)
Tran et al (2012) [33] analyse the cost-effectiveness and
budget impact of the methadone maintenance treatment
(MMT) programme in HIV prevention and treatment among
injection drug users (DUs) in Vietnam.
Vietnam 2012 CEA injection drug users (DUs) Decision trees 1 year Health-care sector
Zarkin (2012) [3] builds a Discrete event simulation to
estimate the net societal benefits of diverting eligible
poisoners to community based treatment in the U.S.
The U.S 2012 CBA A cohort of individuals who are
incarcerated in the state prison
system in the United States
Discrete event
simulation
Life time Societal
Zarkin et al. (2005) [2] estimate net societal benefits of
providing methadone treatment in the U.S using Monte
Carlo simulation model.
The U.S 2005 CBA The general population aged 18–60
(a percentage is heroin users)
Individual-based
microsimulation
Life time Societal
Rydell et al. (1994) [61] presents a model that estimates the
relative cost-effectiveness of four cocaine-control programs:
three "supply control" programs (source-country control,
interdiction, and domestic enforcement) and a "demand
control" program (treating heavy users).
The U.S 1996 CEA The market includes the supply
and demand of cocaine
Aggregate model 15 years Societal
Cartwright (2000) [34] estimates the benefits of reduced
cocaine consumption in terms of reduced societal costs
resulting from the introduction of a medication for cocaine
dependence with a small incremental treatment effect.
The U.S 2000 CBA Heavy cocaine users Decision trees 1 year Societal
Ciketic et al. (2015) [53] evaluates the cost-effectiveness of
counselling as a treatment option for illicit MA use compared
with no treatment option.
Australia 2015 CEA Individuals recruited into
Methamphetamine Treatment
Evaluation Study (MATES)
Decision trees 3 years Societal
Alistar et al. (2014) [54] estimated the effectiveness and cost
effectiveness of strategies for using oral PrEP in various
combinations with methadone maintenance treatment (MMT)
and antiretroviral treatment (ART) in Ukraine, a representative
case for mixed HIV epidemics.
Ukraine 2014 CEA A population of non-IDUs, IDUs who
inject opiates, and IDUs in MMT,
adding an oral PrEP program
(tenofovir/emtricitabine, 49 %
susceptibility reduction) for
uninfected IDUs.
Markov 20 years Health care sector
Angus et al. (2014) [55] adapt the Sheffield Alcohol Policy
Model to evaluate a programme of screening and brief
interventions (SBI) in Italy. Results are reported as Incremental
Cost-Effectiveness Ratios (ICERs) of SBI programmes versus a
‘do-nothing’ scenario.
Italy 2014 CEA General population who visit GPs Decision trees 30 years Societal
Jackson et al. (2015) [56] estimate the cost-effectiveness of
injectable extended release naltrexone (XR-NTX) compared
to methadone maintenance and buprenorphine maintenance
treatment (MMT and BMT respectively) for adult males
enrolled in treatment for opioid dependence in the United
States from the perspective of state-level addiction treatment
payers.
The U.S 2015 CEA Adult males enrolled in treatment for
opioid
dependence
Markov 6 months Health care sector
Laramee et al (2014) [57] investigate whether nalmefene
combined with psychosocial support is cost-effective
compared with psychosocial support alone for reducing
alcohol consumption in alcohol-dependent patients with
high/very high drinking risk levels (DRLs) as defined by the
WHO, and to evaluate the public health benefit of reducing
harmful alcohol-attributable diseases, injuries and deaths.
The U.K
(England and
Wales)
2014 CEA The licensed population for
nalmefene
Markov 5 years Health care sector
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Table 3 Summary of papers and classification of modelling approaches, timeframe and perspectives in costs and benefits (Continued)
Schackman et al (2015) [62] evaluate the cost-effectiveness of
rapid hepatitis C virus (HCV) and simultaneous HCV/HIV
antibody testing in substance abuse treatment programs.
The U.S 2014 CEA Opioid users in substance abuse
treatment programs
Decision trees Life time Health care sector
Thanh et al (2014) [63] used a decision analytic modeling
technique to estimate the incremental cost–effectiveness
ratio and the net monetary benefit of the Parent–Child
Assistance Program (P-CAP) within the Alberta Fetal Alcohol
Spectrum Disorder Service Networks in Canada.
Canada 2015 CEA Women who abuse substances
(e.g. alcohol and/or drugs) and are
pregnant
Decision trees 3 years Health care sector
Braithwaite et al (2014) [58] estimate the portion of HIV
infections attributable to unhealthy alcohol use and to
evaluate the impact of hypothetical interventions directed at
unhealthy alcohol use on HIV infections and deaths.
Kenya 2014 CEA The Kenyan population System dynamics 20 years Health care sector
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type in 2 papers (5 %). The majority of studies were
conducted in the US (n = 15), the U.K (n = 5),
Australia (n = 4), Canada (n = 3) and the remainder
were from a range of countries. Almost all of the
studies used cost-effectiveness analysis (CEA) as the
analytical method (n = 32), two studies used cost-
benefit analysis (CBA) and the rest used other analyt-
ical methods.
Decision trees
Eleven papers were found to have used a decision tree
modelling approach. The topics ranged from short-term
interventions for alcohol problem such as screening for
alcohol users [28–30]; to relapse prevention for opioid
use [31]; cost-effectiveness of methadone maintenance
treatment (MMT) [32, 33] and providing medications to
reduce cocaine dependence [34]. One paper, Navarro et
al. [29] developed a decision tree model to assess out-
comes and costs of a GP-delivered intervention for alco-
hol misuse for different scenarios (increase in screening;
brief intervention; or a combination of screening and
brief intervention and current practice). This paper,
while providing an assessment of cost-effectiveness of
different alternative interventions at an aggregate level,
it does not take into account the role of individual attri-
butes such as age, use and treatment history among the
participants to determine the outcomes: effectively it
assumes that the effect is the same for all participants.
In the area of Opioid Substitution Treatment (OST),
Tran et al. [32] developed a simulated decision tree
model to evaluate cost-effectiveness of providing metha-
done to HIV-positive drug users in three treatment op-
tions; patients: (i) did not receive any drug substitution
therapy during antiretroviral therapy (ART); (ii) received
ART and MMT in standalone clinics, as currently deliv-
ered in Vietnam; and (iii) patients received ART under
the direct supervision of health workers together with
methadone during daily clinic visits. This model evalu-
ated the outcomes at one-year after entering treatment
and assumed the same treatment effects for all partici-
pants regardless of treatment history or use history.
While these assumptions simplify the analysis and point
to the key results, again they demonstrate the limitations
in capturing the long term value of MMT treatment as
well as the differential treatment effects across participants.
Cohort Markov Models
The majority of the reviewed papers used the cohort
Markov modelling approach (n = 20) and cover a diverse
range of drug and alcohol topics. One example of the ap-
plication of cohort Markov model was an evaluation of
cost-effectiveness of long-term outpatient buprenorphine-
naloxone treatment for opioid dependence in primary care
[35]. The cohort was allocated across four health states
including ‘In Treatment Off Drugs’, ‘In Treatment On
Drugs’, ‘Out of Treatment Off Drugs’, and ‘Out of Treat-
ment On Drugs’. The participants were then transitioned
across states based on fixed transition probabilities. The
outcomes including costs of treatment and QALYs (a util-
ity based quality adjusted life year measurement which
takes the value of 1 if full health and 0 if death) were
attached to the states over the course of 24 months. This
model demonstrates the key evolutions of opioid depend-
ence and treatment over time and sets a clear structure
for economic evaluation of treatment but has several limi-
tations that are common in cohort Markov models. The
lack of personal attributes, opioid use history and treat-
ment history when determining either transition probabil-
ities or costs and benefits of treatment mean that the
model may not reflect the heterogeneity of the heroin
treatment population.
System Dynamics Model
System dynamics modelling is used to account for the
interaction between individuals in the cohort. These
models are commonly used for infectious diseases such
as HIV/AIDs and hepatitis C. For example, system dy-
namics models have been used in assessing the role
methadone treatment has in reducing risky behaviours
and new infections, which further reduces the rate of
HIV infection in the cohort (i.e. feedback loops). We
found three papers that applied this approach. The first
paper examines the effect of needle-syringe programmes
and opiate substitution treatment on the reductions in
hepatitis C virus prevalence in the UK [36]. The rates of
infection are modelled through a system of differential
equations that depend on susceptible and chronic inject-
ing drug users in various interventions. The second
paper evaluates the optimal investment to maximize life
years gained or HIV infections averted in a population
of infected drug users and non-users [37]. The
optimization problem was set up with the objective of
maximizing life years gained or HIV infections averted
taking into account the non-linear growth of HIV infec-
tions. Despite the complexity of such models (and their
relevance for infectious disease) one of the limitations of
the system dynamics model is that it ignores individual
attributes and history thus effectively limiting the het-
erogeneity of the cohort. However, the system dynamics
modelling has an ability to depict the interaction among
entities, which is crucial to obtain valid outcomes in the
treatment and prevention of infectious diseases.
Individual Based Models
We found only two papers that met the review inclu-
sion criteria for individual based microsimulation
model. The first estimated the costs and benefits of
providing methadone treatments in the context of the
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U.S. Here, Zarkin et al. [2] built an individual-based
microsimulation that simulated the life time trajector-
ies of a cohort of heroin users beginning at age 18
and ending at age 60. The participants cycled in and
out of five mutually exclusive states including: (i) not
using drugs and not in treatment; (ii) using drugs and
not in treatment; (iii) in treatment; (iv) in prison and
not using drugs and (v) in prison and using drugs.
The key individual attributes such as age, gender,
current heroin use, heroin use history and treatment
history were used to determine the transition prob-
abilities. While providing valuable results, the lack of
data necessitated several simplifying assumptions.
These included the assumption that the only treat-
ment available was opioid substitution treatment and
the transition probabilities were assumed to depend
on only a few key individual attributes and heroin use
and treatment history [2].
A second paper by Zarkin et al. [3] used a Discrete
event simulation to assess the lifetime costs and benefits
of diverting substance-abusing offenders from state
prison to community-based treatment based on the
premise that those offenders who undertook treatment
have decreased criminal recidivism rates translating to
costs-savings to the criminal justice system and gains
from increasing probability of re-entering the labour
market of offenders. This model captured the key events
in the offenders’ lifetime such as substance abuse, crim-
inal activity, employment and treatment history and the
transition probabilities are dependent on age, gender,
and race and treatment history.
Other models
There are other ad-hoc modelling approaches, which are
designed and used by researchers to conduct economic
evaluations in particular circumstances that do not fit in
the mainstream modelling paradigms. Two such papers
are briefly described. Rydell et al. [38] modelled demand
in the cocaine market that depended on the number of
users, initiation rate, escalating and de-escalating use
rates; and supply in the cocaine market that depended
on the production amount minus the seized amount.
The model was used to estimate the impact of different
interventions such as treatment or law enforcement on
supply and demand, from which different cost-effectiveness
indicators can be compared. Magnus et al. [39] estimated
the economic benefits to health, productivity and leisure
due to a reduction of alcohol consumption with reference
to the Australian population in 2008. They collected data
about health and employment corresponding to different
levels of alcohol consumption, from which economic
benefits at different levels of alcohol consumption
were estimated. These models provide population
based evaluation outcomes, but do not take into
account the complexity of disease evaluation such as
interaction, recurrent events and heterogeneity of
study subjects.
Perspectives on costs and benefits
The majority of the reviewed papers adopted a health
care sector perspective (n = 26). The remaining papers
adopted a broader perspective of costs and benefits by
incorporating the social costs such as the impact of
crime and benefits of employment in the evaluations of
treatments [2, 3]. In assessing treatment interventions
for alcohol and drug problems, it is clear that the
selected perspective will impact on which costs and ben-
efits are chosen and might impact on the assessment of
net benefits of treatments enormously.
Time frame
The use of modelling permits examination of a longer
time frame for economic outcomes, superior to eco-
nomic evaluations conducted on individual RCT’s with
foreshortened timeframes. When the process is pro-
tracted as is frequently the case with dependence on
drugs or alcohol, and thus where the costs and benefits
of treatment are cumulative a longer timeframe is more
appropriate. For the policy maker, this means economic
projections into the distant future (and beyond the elect-
oral cycle). The time frames used in the selected papers
vary: there are six papers used 0-1 years; nine papers
used 1-10 years and 23 papers used 10 years to life time.
The majority of papers used cohort Markov, ISM and
System Dynamics adopted long-term timeframe (e.g. ten
years and up to lifetime). Zarkin et al. [2] illustrated that
the choice of timeframe significantly influences the re-
sults in their study about the benefits and costs of
methadone treatment in the U.S. They found that the
benefit-cost ratio of methadone treatment produced
from the lifetime model (37.72:1) was far more than the
benefit-cost ratio from a static model of a one-off inter-
vention (4.86:1).
Discussion and conclusions
Economic evaluations that incorporate modelling play
an important role in producing realistic evidence for pol-
icy making around health interventions for drug and
alcohol problems. The complexity of including the re-
source implications across multiple domains, including
behaviours such as initiating drug use, increasing use,
cycling in and out of treatment or prison during which
previous events may alter the drug users’ future life tra-
jectories and affect the success of future treatments
makes modelling in this field particularly challenging.
The decision tree modelling approach is a relatively
easy technique for comparing different health interven-
tions across a wide range of topics; however, it is not an
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optimal method when the population or treatment
effects are heterogeneous, or when there are recurrent
events, or when the outcome of interest is long-term. To
this end, decision tree modelling may not be sufficient
for evaluating treatments for alcohol and drugs.
On the other hand, the cohort Markov modelling
maybe sufficiently sophisticated in that it may be able to
replicate many of the potential developments in a dis-
ease process through the use of a series of health states.
Particularly, it can account for both the time dimension
by moving participants over time (e.g. time steps) and
the heterogeneity of cohort by allocating them into rele-
vant (but limited) states (e.g. poor health vs good health;
types of treatment; drug dependent vs. not drug
dependent). Attaching associated costs and benefits to
states enables economic evaluations of various health in-
terventions to be conducted. Although permitting more
complex analyses than decision tree models, the Markov
model relies on some major simplifications. First, it does
not take into account the memory of past events that
may shape participants’ future transitions. In other
words, the transition probabilities from one state to
other possible states are fixed at any time in the model
regardless of individual histories. Thus, these models
cannot account for the number or length of previous
treatment episodes. Secondly, it is often not feasible to
take into account the full spectrum of heterogeneity of
the population of interest in a Markov model. Again, this
is a limitation if it is expected that these factors will
significantly impact on the outcomes or costs.
In the area of interventions for drug and alcohol prob-
lems, the individual based model is a powerful tool as it
is possible to simulate multiple events such as initiating
heroin use, becoming dependent, cycling in and out of
various modalities of treatment, entering and exiting
prison over a period of time. The shortcomings in the
Markov model are addressed by (i) incorporating the
past events and personal attributes in determining tran-
sition probabilities; (ii) simulating participants’ life tra-
jectories individually rather than allocating participants
into compartments; (iii) being flexible in time steps
permitting participants to transit to the next state at
different time intervals; (iv) providing a long-term per-
spective on costs and benefits of a series of health inter-
ventions over the participants’ life time. However, a
challenge Individual-based model is that it requires a
large number of parameters to characterise the complex-
ity of transitions across states and at different times and
dependence on individual attributes.
The selection of a modelling approach is likely subject
to the costs and time of model building. When evidence
is required quickly, a decision tree can provide an initial
estimation. However, when the problem pertains to mul-
tiple domains such as scaling up OST treatment and
with substantial budget allocation, more complex models
such as ISM or DES would be preferable.
The choice of an appropriate modelling approach,
time frame and perspective of costs and benefits for a
study may change the modelling results and policy im-
plications significantly. Despite there is ample literature
about the guidelines to identify an appropriate modelling
framework [20], there is not sufficient justification and
discussion about the choice of modelling aspects to
match the complexity of an intervention in the reviewed
papers. It is not uncommon to see different modelling
approaches, time frames and perspectives of costs and
benefits were used to examine a similar type of research
questions. For example, in regarding to economic evalu-
ation of methadone treatment, the time frames ranged
from 1 year [33] to life time [2]; various modelling
approaches were used ranging from decision tree [32],
cohort Markov [40] and individual-based microsimula-
tion [2]; and both health care sector and societal per-
spectives of costs and benefits were used [2, 33]. The
other study also concluded the same findings with this
review, where the authors pointed out that there is no
consistent measuring framework of costs and benefits
regarding to alcohol treatment [41]. Therefore, there is a
pressing need to improve the transparency in modelling
practice by offering justification for the choice of model-
ling aspects. The characteristics and consequences of an
intervention should be discussed and the choice of mod-
elling aspects should be justified. The interested readers
may consult literature about modelling guidelines in
health economics to aid their decision [20–22].
A limitation of this review is that it only focused on
three main aspects used in study that include modelling
approach, time frame and perspectives of costs and ben-
efits, but not the process of decision about the choices
of modelling aspects. Although this review have critically
appraised a number of papers with respect to the appro-
priateness of the above modelling aspects, future re-
search should evaluate the characteristics, effects and
consequences of the intervention and recommend suit-
able modelling approach, time frame and perspectives of
costs and benefits. This will provide evidence about the
difference between the ideal model and the chosen
model in the research of drug and alcohol intervention.
Additional file
Additional file 1: References to the list of selected papers for review.
(DOC 84 kb)
Abbreviations
ABM: agent-based models; ART: antiretroviral therapy; CEA: cost-effectiveness
analysis; DES: discrete event simulations; MMT: methadone maintenance
treatment; OST: opioid substitution treatment; QALYs: quality-adjusted life
years; RCTs: randomised control trials; SD: system dynamics models.
Hoang et al. BMC Health Services Research  (2016) 16:127 Page 12 of 14
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
VPH, MS, NS and AR participated in the study concept and design,
analysing the literature, and drafting and revising the manuscript.
PP and MF participated in the study concept and design and drafting
and revising the manuscript. All authors read and approved the final
manuscript.
Acknowledgements
This paper was supported by Project Grant number APP1042923 from
National Medical and Health Research Council (NMHRC) of Australia.
The funder has no knowledge about this study.
Author details
1Drug Policy Modelling Program, National Drug and Alcohol Research
Centre, University of New South Wales, Sydney, NSW 2031, Australia. 2SMART
Infrastructure Facility, University of Wollongong, Wollongong, NSW 2522,
Australia. 3National Drug and Alcohol Research Centre, University of New
South Wales, Sydney, NSW 2031, Australia.
Received: 14 May 2015 Accepted: 29 March 2016
References
1. Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of disease
attributable to illicit drug use and dependence: findings from the Global
Burden of Disease Study 2010. Lancet. 2013;382:1564–74.
2. Zarkin GA, Dunlap LJ, Hicks KA, et al. Benefits and costs of methadone
treatment: results from a lifetime simulation model. Health Econ. 2005;14:
1133–50.
3. Zarkin GA, Cowell AJ, Hicks KA, et al. Lifetime benefits and costs of diverting
substance-abusing offenders from state prison. Crime Delinquency. 2012;
XX(X):1–22.
4. NHMRC. How to compare the costs and benefits: evaluation of the
economic evidence. Canberra: NHMRC; 2001.
5. Harris AH, Gospodarevskaya E, Ritter AJ. A randomised trial of the cost
effectiveness of buprenorphine as an alternative to methadone
maintenance treatment for heroin dependence in a primary care setting.
Pharmacoeconomics. 2005;23:77–91.
6. Bell J, Shanahan M, Mutch C, et al. A randomized trial of effectiveness and
cost-effectiveness of observed versus unobserved administration of
buprenorphine-naloxone for heroin dependence. Addiction. 2007;102:
1899–907.
7. Doran CM. Buprenorphine, buprenorphine/naloxone and methadone
maintenance: a cost-effectiveness analysis. Expert Rev Pharmacoecon
Outcomes Res. 2005;5:583–91.
8. Barnett PG, Zaric GS, Brandeau ML. The cost-effectiveness of buprenorphine
maintenance therapy for opiate addiction in the United States. Addiction.
2001;96:1267–78.
9. Vanagas G, Padaiga Z, Bagdonas E. Cost-utility analysis of methadone
maintenance treatment in Lithuania. Medicina (Kaunas). 2010;46:286–92.
10. Eisenberg K, Woodruff SI. Randomized controlled trial to evaluate
screening and brief intervention for drug-using multiethnic emergency
and trauma department patients. Addict Sci Clin Pract. 2013;8(1):8.
doi:10.1186/1940-0640-8-8.
11. Saitz R, Palfai TA, Cheng DM, et al. Screening and brief intervention for drug
use in primary care: the ASPIRE randomized clinical trial. JAMA. 2014;312(5):
502–13.
12. Sindelar JL, Jofre-Bonet M, French MT, et al. Cost-effectiveness analysis of
addiction treatment: paradoxes of multiple outcomes. Drug Alcohol
Depend. 2004;73:41–50.
13. Shanahan M, Ritter A. Confronting the challenges of conducting a CBA of
cannabis policies. Drugs. 2013;20:175–83.
14. Sareen J, Chartier M, Paulus MP, et al. Illicit drug use and anxiety disorders:
findings from two community surveys. Psychiatry Res. 2006;142:11–7.
15. Degenhardt L, Larney S, Randall D, et al. Causes of death in a cohort treated
for opioid dependence between 1985 and 2005. Addiction. 2014;109:90–9.
16. Darke S, Mills KL, Ross J, et al. Rates and correlates of mortality
amongst heroin users: findings from the Australian Treatment
Outcome Study (ATOS), 2001-2009. Drug Alcohol Depend. 2011;115:
190–5.
17. Lamotte M, Annemans L, Lefever A, et al. A health economic model to
assess the long-term effects and cost-effectiveness of orlistat in obese type
2 diabetic patients. Diabetes Care. 2002;25:303–8.
18. Schroettner J, Lassnig A. Simulation model for cost estimation of
integrated care concepts of heart failure patients. Health Econ Rev.
2013;3:26.
19. Buxton MJ, Drummond MF, Van Hout BA, et al. Modelling in economic
evaluation: an unavoidable fact of life. Health Econ. 1997;6:217–27.
20. Brennan A, Chick SE, Davies R. A taxonomy of model structures for economic
evaluation of health technologies. Health Econ. 2006;15:1295–310.
21. Barton P, Bryan S, Robinson S. Modelling in the economic evaluation of
health care: selecting the appropriate approach. J Health Serv Res Policy.
2004;9:110–8.
22. Gray A, Clarke PM, Wolstenholme P, Wordsworth S. Applied Methods of
Cost-effectiveness Analysis in Healthcare (Handbooks in Health Economic
Evaluation). Oxford: Oxford University Press; 2010.
23. Paddock SM, Kilmer B, Caulkins JP, et al. An epidemiological model for
examining marijuana use over the life course. Epidemiol Res Int. 2012;
2012:12.
24. Perez P, Dray A, Ritter A, Dietze P, Moore T, Mazerolle L. SimDrug:
tackling the complexity of illicit drug markets in Australia. In: Perez P,
Batten D, editors. Complex Science for a Complex World. Exploring
Human Ecosystems with Agents. Canberra: ANU E Press; 2006.
p. 193–224.
25. Moore D, Dray A, Green R, et al. Extending drug ethno-epidemiology using
agent-based modelling. Addiction. 2009;104:1991–7.
26. Meier PS, Purshouse R, Brennan A. Policy options for alcohol price
regulation: the importance of modelling population heterogeneity.
Addiction. 2010;105:383–93.
27. White IR, Altmann DR, Nanchahal K. Alcohol consumption and
mortality: modelling risks for men and women at different ages. BMJ.
2002;325:191–94.
28. Downs SM, Klein JD. Clinical preventive services efficacy and adolescents'
risky behaviors. Arch Pediatr Adolesc Med. 1995;149:374–9.
29. Navarro HJ, Shakeshaft A, Doran CM, et al. The potential cost-effectiveness
of general practitioner delivered brief intervention for alcohol misuse:
evidence from rural Australia. Addict Behav. 2011;36:1191–8.
30. Purshouse RC, Brennan A, Rafia R, et al. Modelling the cost-effectiveness of
alcohol screening and brief interventions in primary care in England.
Alcohol Alcohol. 2013;48:180–88.
31. Adi Y, Juarez-Garcia A, Wang D, et al. Oral naltrexone as a treatment
for relapse prevention in formerly opioid-dependent drug users: a
systematic review and economic evaluation. Health Technol Assess.
2007;11:iii-iv, 1-85.
32. Tran BX, Ohinmaa A, Duong AT, et al. Cost-effectiveness of integrating
methadone maintenance and antiretroviral treatment for HIV-positive drug
users in Vietnam's injection-driven HIV epidemics. Drug Alcohol Depend.
2012;125:260–6.
33. Tran BX, Ohinmaa A, Duong AT, et al. The cost-effectiveness and budget
impact of Vietnam's methadone maintenance treatment programme in HIV
prevention and treatment among injection drug users. Glob Public Health.
2012;7:1080–94.
34. Cartwright WS. Cocaine medications, cocaine consumption and societal
costs. Pharmacoeconomics. 2000;18:405–13.
35. Schackman BR, Leff JA, Polsky D, Moore BA, et al. Cost-effectiveness of long-
term outpatient buprenorphine-naloxone treatment for opioid dependence
in primary care. J Gen Intern Med. 2012;27(6):669–76.
36. Vickerman P, Martin N, Turner K, et al. Can needle and syringe programmes
and opiate substitution therapy achieve substantial reductions in hepatitis C
virus prevalence? Model projections for different epidemic settings.
Addiction. 2012;107:1984–95.
37. Zaric GS, Brandeau ML. Optimal investment in a portfolio of HIV prevention
programs. Med Decis Making. 2001;21:391–408.
38. Rydell CP, Everingham SS. Controlling cocaine: Supply versus demand
programs. Santa Monica, CA: RAND Corp; 1994. http://www.rand.org/pubs/
monograph_reports/MR331.html.
39. Magnus A, Cadilhac D, Sheppard L, et al. The economic gains of achieving
reduced alcohol consumption targets for Australia. Am J Public Health.
2012;102:1313–19.
Hoang et al. BMC Health Services Research  (2016) 16:127 Page 13 of 14
40. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis
C treatment for injecting drug users on methadone maintenance in New
Zealand? Drug Alcohol Rev. 2004;23:261–72.
41. Barbosa C, Godfrey C, Parrott S. Methodological assessment of economic
evaluations of alcohol treatment: what is missing? Alcohol Alcohol. 2010;
45(1):53–63. doi:10.1093/alcalc/agp067.
42. Coffin PO, Sullivan SD. Cost-Effectiveness of Distributing Naloxone to Heroin
Users for Lay Overdose Reversal. Ann Intern Med. 2013;158:1–U42.
43. Zaric GS, Barnett PG, Brandeau ML. HIV transmission and the cost-
effectiveness of methadone maintenance. Am J Public Health. 2000;90:
1100–11.
44. Tariq L, van den Berg M, Hoogenveen RT, et al. Cost-effectiveness of an
opportunistic screening programme and brief intervention for excessive
alcohol use in primary care. PLoS ONE [Electronic Resource]. 2009;4: e5696.
45. van den Berg M, van Baal PHM, Tariq L, et al. The cost-effectiveness of
increasing alcohol taxes: a modelling study. BMC Med. 2008;6.
46. Nosyk B, Guh DP, Bansback NJ, et al. Cost-effectiveness of diacetylmorphine
versus methadone for chronic opioid dependence refractory to treatment.
CMAJ. 2012;184:E317–28.
47. Mortimer D, Segal L. Economic evaluation of interventions for problem
drinking and alcohol dependence: Cost per QALY estimates. Alcohol
Alcohol. 2005;40:549–55.
48. Palmer AJ, Neeser K, Weiss C, et al. The long-term cost-effectiveness of
improving alcohol abstinence with adjuvant acamprosate. Alcohol Alcohol.
2000;35:478–92.
49. Zaric GS, Brandeau ML, Barnett PG. Methadone maintenance and HIV
prevention: A cost-effectiveness analysis. Manage Sci. 2000;46:1013–31.
50. Barnett PG. The cost-effectiveness of methadone maintenance as a health
care intervention. Addiction. 1999;94:479–88.
51. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised
injection facility. CMAJ. 2008;179:1143–51.
52. Kapoor A, Kraemer KL, Smith KJ, et al. Cost-effectiveness of screening for
unhealthy alcohol use with % carbohydrate deficient transferrin: results
from a literature-based decision analytic computer model. Alcoholism. 2009;
33:1440–9.
53. Ciketic S, Hayatbakhsh R, McKetin R, et al. Cost-effectiveness of counselling
as a treatment option for methamphetamine dependence. J Subst Use.
2015;20:239–46.
54. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of
oral pre-exposure prophylaxis in a portfolio of prevention programs for
injection drug users in mixed HIV epidemics. PLoS One. 2014;9, e86584.
55. Angus C, Scafato E, Ghirini S, et al. Cost-effectiveness of a programme of
screening and brief interventions for alcohol in primary care in Italy.
BMC Fam Pract. 2014;15:26.
56. Jackson H, Mandell K, Johnson K, et al. Cost-Effectiveness of Injectable
Extended-Release Naltrexone Compared With Methadone Maintenance
and Buprenorphine Maintenance Treatment for Opioid Dependence.
Subst Abus. 2015;36:226–31.
57. Laramee P, Brodtkorb TH, Rahhali N, et al. The cost-effectiveness and public
health benefit of nalmefene added to psychosocial support for the
reduction of alcohol consumption in alcohol-dependent patients with
high/very high drinking risk levels: a Markov model. BMJ Open. 2014;4,
e005376.
58. Braithwaite RS, Nucifora KA, Kessler J, et al. How inexpensive does an
alcohol intervention in Kenya need to be in order to deliver favorable value
by reducing HIV-related morbidity and mortality? J Acquir Immune Defic
Syndr. 2014;66:e54–8.
59. Wammes JJ, Siregar AY, Hidayat T, et al. Cost-effectiveness of methadone
maintenance therapy as HIV prevention in an Indonesian high-prevalence
setting: A mathematical modeling study. International Journal of Drug
Policy. 2012;23:358–64.
60. Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of
expanding harm reduction and antiretroviral therapy in a mixed HIV
epidemic: a modeling analysis for Ukraine. PLoS Medicine / Public Library of
Science. 2011;8:e1000423.
61. Rydell CP, & Everingham SS. Controlling cocaine: Supply versus demand
programs, Drug Policy Research Centre, RAND Corp. 1994.
62. Schackman BR, Leff JA, Barter DM, et al. Cost-effectiveness of rapid
hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV
testing in substance abuse treatment programs. Addiction (Abingdon,
England). 2015;110:129–43.
63. Thanh NX, Jonsson E, Moffatt J, et al. An Economic Evaluation of the
Parent–Child Assistance Program for Preventing Fetal Alcohol Spectrum
Disorder in Alberta, Canada. Administration and Policy in Mental Health and
Mental Health Services Research. 2014;42:10–18.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Hoang et al. BMC Health Services Research  (2016) 16:127 Page 14 of 14
